We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-11.64%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
-$306M
Cap. Flow
-$59.1M
Cap. Flow %
-5.47%
Top 10 Hldgs %
66.39%
Holding
80
New
21
Increased
8
Reduced
13
Closed
16

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
2
MRK icon
Merck
MRK
+$18.4M
3
ALGN icon
Align Technology
ALGN
+$11.1M
4
HRTX icon
Heron Therapeutics
HRTX
+$8.1M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.87M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18.8M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.4M
3
FATE icon
Fate Therapeutics
FATE
+$15.1M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOMX
76
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-1,162,176
Closed -$3.87M
DERM
77
DELISTED
Dermira, Inc.
DERM
– –
-545,466
Closed -$8.27M
ARQL
78
DELISTED
Arqule Inc
ARQL
– –
-387,469
Closed -$7.73M
MDCO
79
PUT
DELISTED
Medicines Co
MDCO
– –
-110,000
Closed -$9.34M
1 2 3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2020 Portfolio in Review

As of Q1 2020, Sofinnova Investments held 80 positions worth $1.08B, down 22% from $1.39B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments withdrew a net $59.1M in Q1 2020, closing 16 positions and reducing 13 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Alexion Pharmaceuticals worth $27.6M.

  • Sofinnova Investments's largest Q1 2020 buy was Alexion Pharmaceuticals: 307,300 shares worth $27.6M.
  • Sofinnova Investments added most to Merck in Q1 2020, an estimated $18.4M increase.
  • Sofinnova Investments's biggest Q1 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.4M.
  • Sofinnova Investments fully exited Regeneron Pharmaceuticals in Q1 2020, selling an estimated $18.8M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $1.08B portfolio in Q1 2020.
  • Sofinnova Investments opened 21 new positions and closed 16 in Q1 2020.
  • Sofinnova Investments's portfolio value fell 22% quarter-over-quarter to $1.08B.

Based on Sofinnova Investments's 13F filing for Q1 2020, filed 13 May 2020.